Development of the Commercial Manufacturing Process for Ipatasertib.
Chimia (Aarau)
; 75(7): 605-613, 2021 Aug 25.
Article
em En
| MEDLINE
| ID: mdl-34523401
ABSTRACT
Ipatasertib is a potent small molecule Akt kinase inhibitor currently being tested in Phase III clinical trials for the treatment of metastatic castration-resistant prostate cancer and triple negative metastatic breast cancer. In this paper an overview of the development achievements towards the commercial manufacturing process is given. The convergent synthesis consists of ten steps with eight isolated intermediates and utilizes a wide range of chemical techniques and technologies to build-up this complex drug. All three stereocenters are introduced using enzyme or metal catalysis.
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Protocolos de Quimioterapia Combinada Antineoplásica
/
Neoplasias
Limite:
Humans
/
Male
Idioma:
En
Revista:
Chimia (Aarau)
Ano de publicação:
2021
Tipo de documento:
Article